Long‐term risk of recurrent venous thromboembolism after a first contraceptive‐related event: Data from REVERSE cohort study
David Aziz(University of Ottawa), Grégoire Le Gal(University of Ottawa), Isabelle Chagnon(Université de Montréal), Leslie Skeith(University of Calgary), Elham Sabri(Ottawa Hospital), Susan Solymoss(Montreal General Hospital), Marc Carrier(University of Ottawa), Susan R. Kahn(Jewish General Hospital), Mark Crowther(Population Health Research Institute), Marc Rodger(McGill University), Philip S. Wells(Ottawa Hospital), Michael J. Kovacs(Western University), David R. Anderson(Dalhousie University), Richard H. White(Centre Alpien de Phytogéographie), Marc Righini(University Hospital of Geneva)
Cited by 16
Related Papers
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Prevention of VTE in Nonsurgical Patients
|CHEST Journal|2012|2.7k
Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common Cancers
|Archives of Internal Medicine|2006|1.3k
Evidence-Based Management of Anticoagulant Therapy
|CHEST Journal|2012|1.3k
The epidemiology of venous thromboembolism
|Journal of Thrombosis and Thrombolysis|2016|1.1k